A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Bermekimab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept
- Sponsors XBiotech
- 29 Jan 2019 According to a XBiotech media release, data from the study will be presented at the American Academy of Dermatology (AAD) Annual Meeting 2018.
- 12 Dec 2018 Results presented in a XBiotech Media Release.
- 12 Dec 2018 Status changed from active, no longer recruiting to completed, according to a XBiotech media release.